138 related articles for article (PubMed ID: 24676427)
21. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
Aaronson D; Cowan J; Carroll P; Konety B
BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
[TBL] [Abstract][Full Text] [Related]
22. Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective.
Lee HJ; Lee A; Huang HH; Lau WKO
Int Urol Nephrol; 2018 Apr; 50(4):665-673. PubMed ID: 29492797
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
24. Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy.
Onozawa M; Hinotsu S; Saito A; Uno S; Akaza H
Gan To Kagaku Ryoho; 2021 Jul; 48(7):911-919. PubMed ID: 34267028
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
[TBL] [Abstract][Full Text] [Related]
26. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
27. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
28. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
30. Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?
Ha US; Choi JB; Shim JI; Kang M; Park E; Kang S; Park J; Yang J; Choi I; Ahn J; Kwak C; Jeong CW; Kim CS; Byun SS; Seo SI; Lee HM; Lee SJ; Lee SH; Chung BH; Lee JY
J Natl Compr Canc Netw; 2019 May; 17(5):441-449. PubMed ID: 31085754
[TBL] [Abstract][Full Text] [Related]
31. Modified J-CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy.
Lim J; Hinotsu S; Onozawa M; Malek R; Sundram M; Teh GC; Ong TA; Thevarajah S; Zainal R; Khoo SC; Omar S; Nasuha NA; Akaza H
Cancer Med; 2020 Dec; 9(24):9346-9352. PubMed ID: 33098372
[TBL] [Abstract][Full Text] [Related]
32. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
Onozawa M; Akaza H; Hinotsu S; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Tsukamoto T
Cancer Med; 2018 Oct; 7(10):4893-4902. PubMed ID: 30151999
[TBL] [Abstract][Full Text] [Related]
33. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
[TBL] [Abstract][Full Text] [Related]
34. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
35. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.
Akaza H; Hinotsu S; Usami M; Ogawa O; Kitamura T; Suzuki K; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M
Prostate Int; 2013; 1(2):81-8. PubMed ID: 24223407
[TBL] [Abstract][Full Text] [Related]
37. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
38. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009.
Tanaka N; Hirayama A; Yoneda T; Yoshida K; Shimada K; Konishi N; Fujimoto K
BMC Cancer; 2013 Dec; 13():588. PubMed ID: 24325407
[TBL] [Abstract][Full Text] [Related]
39. Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?
Lu-Yao GL; Albertsen PC; Li H; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2012 Dec; 62(6):966-72. PubMed ID: 22608160
[TBL] [Abstract][Full Text] [Related]
40. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
